EICHOR
● Active Not Recruiting
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Condition: Multiple Myeloma · Sponsor: Intergroupe Francophone du Myelome
About this study
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria. This is a multicenter, prospective, observational study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (31)
| CHU Amiens Picardie | Amiens, France | — |
| CH d'ANNECY | Annecy, France | — |
| Centre hospitalier d'Argenteuil | Argenteuil, France | — |
| Hopital de la cote Basque | Bayonne, France | — |
| CHU de Besançon | Besançon, France | — |
| CHU Bordeaux | Bordeaux, France | — |
| Centre hospitalier de Brive-la-Gaillarde | Brive-la-Gaillarde, France | — |
| CHU CAEN | Caen, France | — |
| Centre hospitalier Métropole de Savoie | Chambéry, France | — |
| CHU Clermont-Ferrand Site Estaing | Clermont-Ferrand, France | — |
| CHU Henri Mondor | Créteil, France | — |
| Chu Dijon | Dijon, France | — |
+ 19 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06062537